JP2019512216A - カルシウムチャネルのペプチド阻害剤 - Google Patents

カルシウムチャネルのペプチド阻害剤 Download PDF

Info

Publication number
JP2019512216A
JP2019512216A JP2018544213A JP2018544213A JP2019512216A JP 2019512216 A JP2019512216 A JP 2019512216A JP 2018544213 A JP2018544213 A JP 2018544213A JP 2018544213 A JP2018544213 A JP 2018544213A JP 2019512216 A JP2019512216 A JP 2019512216A
Authority
JP
Japan
Prior art keywords
functional fragment
polypeptide
polypeptide according
calcium channel
splunc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018544213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512216A5 (enExample
Inventor
タラン，ロバート
ウー，トンドゥ
Original Assignee
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル filed Critical ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Publication of JP2019512216A publication Critical patent/JP2019512216A/ja
Publication of JP2019512216A5 publication Critical patent/JP2019512216A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018544213A 2016-02-22 2017-02-22 カルシウムチャネルのペプチド阻害剤 Pending JP2019512216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298204P 2016-02-22 2016-02-22
US62/298,204 2016-02-22
PCT/US2017/018840 WO2017147128A1 (en) 2016-02-22 2017-02-22 Peptide inhibitors of calcium channels

Publications (2)

Publication Number Publication Date
JP2019512216A true JP2019512216A (ja) 2019-05-16
JP2019512216A5 JP2019512216A5 (enExample) 2020-04-09

Family

ID=59685595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544213A Pending JP2019512216A (ja) 2016-02-22 2017-02-22 カルシウムチャネルのペプチド阻害剤

Country Status (9)

Country Link
US (1) US10894811B2 (enExample)
EP (1) EP3419994B1 (enExample)
JP (1) JP2019512216A (enExample)
AU (1) AU2017222450A1 (enExample)
BR (1) BR112018017144A2 (enExample)
ES (1) ES2979122T3 (enExample)
IL (1) IL261265A (enExample)
MX (1) MX2018010132A (enExample)
WO (1) WO2017147128A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511119A (ja) * 2021-03-22 2024-03-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 修飾されたペプチド模倣薬および使用方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3554527A1 (en) * 2016-12-13 2019-10-23 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528300A (ja) * 2000-02-24 2003-09-24 オックスフォード グリコサイエンセス（ユーケー） リミテッド 神経精神及び神経障害におけるｄｐｉ−６、推定上の治療ターゲットおよびバイオマーカー
US20090104177A1 (en) * 2004-06-29 2009-04-23 Forschungsverbund Berlin E.V. Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
US20140228276A1 (en) * 2011-09-20 2014-08-14 The University Of North Carolina At Chapel Hill Regulation of Sodium Channels by PLUNC Proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
CA2271325A1 (en) 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
US20050192221A1 (en) * 2003-12-04 2005-09-01 Mccray Paul B.Jr. Methods and compositions related to plunc polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528300A (ja) * 2000-02-24 2003-09-24 オックスフォード グリコサイエンセス（ユーケー） リミテッド 神経精神及び神経障害におけるｄｐｉ−６、推定上の治療ターゲットおよびバイオマーカー
US20090104177A1 (en) * 2004-06-29 2009-04-23 Forschungsverbund Berlin E.V. Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
US20140228276A1 (en) * 2011-09-20 2014-08-14 The University Of North Carolina At Chapel Hill Regulation of Sodium Channels by PLUNC Proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 305, JPN6021004176, 2013, pages 990 - 1001, ISSN: 0004440759 *
BBRC, vol. Vol.385(1):49, JPN6021004181, 2009, ISSN: 0004440761 *
BIOCHEM.J., vol. 445, JPN6021004183, 2012, pages 29 - 38, ISSN: 0004440762 *
EXPERIMENTAL NEUROLOGY, vol. 189, JPN6021004188, 2004, pages 5 - 9, ISSN: 0004440764 *
JBC, vol. 285, JPN6021004178, 2010, pages 5066 - 5075, ISSN: 0004440760 *
PLOS ONE, vol. Vol.8,Issue 12, e82944, JPN6021004185, 2013, ISSN: 0004440763 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511119A (ja) * 2021-03-22 2024-03-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 修飾されたペプチド模倣薬および使用方法

Also Published As

Publication number Publication date
US10894811B2 (en) 2021-01-19
BR112018017144A2 (pt) 2019-01-15
ES2979122T3 (es) 2024-09-24
EP3419994B1 (en) 2024-05-08
AU2017222450A1 (en) 2018-09-27
IL261265A (en) 2018-10-31
EP3419994A1 (en) 2019-01-02
EP3419994C0 (en) 2024-05-08
EP3419994A4 (en) 2019-11-06
US20190062386A1 (en) 2019-02-28
WO2017147128A1 (en) 2017-08-31
MX2018010132A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
DK2760463T3 (en) REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
US20170080053A1 (en) Regulation of sodium channels by plunc proteins
EP3865146A1 (en) Prophylactic or therapeutic drug for benign tumor
US20020077289A1 (en) Angiostatin and endostatin binding proteins and methods of use
US10894811B2 (en) Peptide inhibitors of calcium channels
US9186388B2 (en) Wnt1 for treatment of cardiovascular disorders and injuries
US20220401515A1 (en) Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases
US20230295263A1 (en) Soluble thy-1 compositions and use thereof to treat or reverse fibrosis
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
US8530174B2 (en) SOGA polynucleotides and polypeptides and uses thereof
US20230348566A1 (en) Re-folded human serum albumin and use thereof for anti-tumor
KR20230068866A (ko) 결핵균의 Rv3364c 단백질에서 유래한 패혈증 치료용 펩타이드
HK40056363A (en) Peptide therapeutics for the treatment of cancer and uses thereof
HK40051038A (en) Prophylactic or therapeutic drug for benign tumor
HK1200729B (en) Regulation of sodium channels by plunc proteins
JP2009502904A (ja) 補体Ｃ３ａ由来のペプチド及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210928